HER2+ Breast Cancer | Specialty

Managing Cardiac AEs in HER2-Positive Breast Cancer

March 16th 2018

Jean-Bernard Durand, MD, discusses the possibility of repairing cardiac damage in patients with HER2-positive breast cancer.

Dr. Mittendorf on the Impact of Pertuzumab in HER2+ Breast Cancer

March 13th 2018

Elizabeth A. Mittendorf, MD, PhD, associate professor in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center, discusses the impact of pertuzumab (Perjeta) on the treatment landscape of HER2-positive breast cancer.

Dr. Hurvitz on Novel Emerging Agents in HER2+ Breast Cancer

March 11th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses novel agents that are emerging in the HER2-positive breast cancer space. Hurvitz shared this insight in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.

Dual Targeting Advances in HER2+/HR+ Breast Cancer

March 11th 2018

The discovery of crosstalk between the HER2 and hormone receptor pathways has led to the promising treatment strategy of dual targeting regimens.

Hurvitz Heralds Next HER2+ Breast Cancer Breakthroughs

March 10th 2018

Several new agents have emerged in HER2-positive breast cancer with the potential to further alter the natural course of the disease.

Dr. Blackwell Discusses the HER2CLIMB Study in HER2+ Breast Cancer

March 7th 2018

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the HER2CLIMB study in patients with HER2-positive breast cancer.

Blood Test May Predict Palbociclib Response Earlier in Breast Cancer

March 2nd 2018

A blood test that detects early changes in circulating tumor DNA may provide an earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to palbociclib (Ibrance).

European Panel Recommends Against Neratinib for HER2-Positive Breast Cancer

February 23rd 2018

European regulators have recommended against approving a marketing authorization application for the use of neratinib (Nerlynx) as extended adjuvant treatment for women with early stage HER2-positive breast cancer.

Dr. Borgen Discusses HER2 Blockade in Breast Cancer

February 22nd 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses HER2 blockade in the treatment of patients with HER2-positive breast cancer.

Dr. Traina Discusses Neratinib in HER2+ Breast Cancer

February 17th 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Take-Home Messages on Breast Oncology Advances

February 17th 2018

Immunotherapy for Triple-Negative Breast Cancer

February 17th 2018

PARP Inhibitors for BRCA-Mutated TNBC

February 17th 2018

Advantages with Nab-Paclitaxel in TNBC

February 17th 2018

Trastuzumab Deruxtecan for HER2+ Breast Cancer

February 17th 2018

HER2-Targeted Therapy for HER2 Low-Expressing Breast Cancer

February 17th 2018

Adjuvant Therapy for HER2+ Breast Cancer

February 17th 2018

Refining Neoadjuvant Chemotherapy for HER2+ Breast Cancer

February 17th 2018

Ovarian Suppression in Metastatic HR+ Breast Cancer

February 17th 2018

Neoadjuvant Therapy for HR+ Breast Cancer

February 17th 2018